- Home
- XMTR vs ARQT Comparison
XMTR vs ARQT Comparison
Compare XMTR & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XMTR
- ARQT
- Stock Information
- Founded
- XMTR 2013
- ARQT 2016
- Country
- XMTR United States
- ARQT United States
- Employees
- XMTR N/A
- ARQT N/A
- Industry
- XMTR Industrial Machinery/Components
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- XMTR Technology
- ARQT Health Care
- Exchange
- XMTR Nasdaq
- ARQT Nasdaq
- Market Cap
- XMTR 1.6B
- ARQT 1.7B
- IPO Year
- XMTR 2021
- ARQT 2020
- Fundamental
- Price
- XMTR $33.45
- ARQT $13.78
- Analyst Decision
- XMTR Buy
- ARQT Strong Buy
- Analyst Count
- XMTR 11
- ARQT 6
- Target Price
- XMTR $34.82
- ARQT $18.80
- AVG Volume (30 Days)
- XMTR 747.5K
- ARQT 2.0M
- Earning Date
- XMTR 08-07-2025
- ARQT 08-13-2025
- Dividend Yield
- XMTR N/A
- ARQT N/A
- EPS Growth
- XMTR N/A
- ARQT N/A
- EPS
- XMTR N/A
- ARQT N/A
- Revenue
- XMTR $573,810,000.00
- ARQT $212,819,000.00
- Revenue This Year
- XMTR $21.52
- ARQT $61.15
- Revenue Next Year
- XMTR $17.20
- ARQT $37.98
- P/E Ratio
- XMTR N/A
- ARQT N/A
- Revenue Growth
- XMTR 19.35
- ARQT 100.03
- 52 Week Low
- XMTR $11.32
- ARQT $7.86
- 52 Week High
- XMTR $45.33
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- XMTR 52.08
- ARQT 46.51
- Support Level
- XMTR $31.87
- ARQT $13.51
- Resistance Level
- XMTR $34.20
- ARQT $14.31
- Average True Range (ATR)
- XMTR 1.44
- ARQT 0.61
- MACD
- XMTR -0.11
- ARQT -0.01
- Stochastic Oscillator
- XMTR 75.70
- ARQT 46.95
About XMTR Xometry Inc.
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.